In the BioHarmony Drug Report Database
Apokyn, Kynmobi (apomorphine) is a small molecule pharmaceutical. Apomorphine was first approved as Apokyn on 2004-04-20. It is used to treat parkinson disease in the USA. The pharmaceutical is active against D(2) dopamine receptor, D(3) dopamine receptor, and D(4) dopamine receptor. In addition, it is known to target D(1B) dopamine receptor, alpha-2A adrenergic receptor, alpha-2C adrenergic receptor, transient receptor potential cation channel subfamily A member 1, alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 1A, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C. Apokyn’s patents are valid until 2036-04-19 (FDA).
Image (chem structure or protein)